D3822
Dipeptidyl Peptidase IV Inhibitor I
Synonyme(s) :
Diprotin A
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Description générale
Dipeptidyl peptidase IV (DPP IV) is a member of the prolyl-specific proteases family. It is a dimeric type II integral membrane glycoprotein that is broadly expressed in the epithelial and nonepithelial tissues. It is majorly expressed in the kidney and the colon.
Application
Dipeptidyl peptidase IV inhibitor I has been used in acute in vivo studies to assess rapid plasma glucagon-like peptide (GLP-1) responses to specified secretory agents in mice.
Actions biochimiques/physiologiques
Dipeptidyl peptidase IV (DPP IV) functions as a modulator of glucagon-like peptide (GLP-1), insulin-stimulating hormones, and glucose-dependent insulinotropic polypeptide (GIP). It is an essential therapeutic target for type 2 diabetes (T2DM). DPP-4 inhibitors are crucial for maintaining glucose homeostasis by prolonging the activity of GLP-1 and GIP. They also enhance glycemic control for a longer period when compared to early oral hypoglycemics. DPP-4 also acts as a binding protein and a ligand of extracellular factors.
Séquence
Ile-Pro-Ile
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Biomedicines, 11(11) (2023-11-25)
Dipeptidyl peptidase 4 (DPP4) inhibitors, commonly known as gliptins, have been an integral part of the treatment of type 2 diabetes mellitus (T2DM) for several years. Despite their remarkable efficacy in lowering glucose levels and their compatibility with other hypoglycemic
Acta diabetologica, 57(7), 779-783 (2020-06-09)
SARS-CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19. Virus binds to the cell surface receptor ACE2;
Current drug targets, 10(1), 71-87 (2009-01-20)
Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus it is a promising target for the treatment of Type 2 Diabetes mellitus (T2DM). Inhibition of plasma DPP IV
Mini reviews in medicinal chemistry, 19(2), 88-97 (2018-04-26)
Diabetes mellitus is an emerging predator and affecting around 422 million adults worldwide. Higher levels of circulating insulin and increased pressure on the pancreas to produce insulin have been inferred as possible etiology for diabetes leading to a higher risk
Molecular metabolism, 37, 100990-100990 (2020-04-13)
Glucagon-like peptide-1 is a nutrient-sensitive hormone secreted from enteroendocrine L cells within the small and large bowel. Although GLP-1 levels rise rapidly in response to food ingestion, the greatest density of L cells is localized to the distal small bowel
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique